Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations

Dennis C. Turk*, Robert H. Dworkin, Laurie B. Burke, Richard Gershon, Margaret Rothman, Jane Scott, Robert R. Allen, J. Hampton Atkinson, Julie Chandler, Charles Cleeland, Penny Cowan, Rozalina Dimitrova, Raymond Dionne, John T. Farrar, Jennifer A. Haythornthwaite, Sharon Hertz, Alejandro R. Jadad, Mark P. Jensen, David Kellstein, Robert D. KernsDonald C. Manning, Susan Martin, Mitchell B. Max, Michael P. McDermott, Patrick McGrath, Dwight E. Moulin, Turo Nurmikko, Steve Quessy, Srinivasa Raja, Bob A. Rappaport, Christine Rauschkolb, James P. Robinson, Mike A. Royal, Lee Simon, Joseph W. Stauffer, Gerold Stucki, Jane Tollett, Thorsten von Stein, Mark S. Wallace, Joachim Wernicke, Richard E. White, Amanda C. Williams, James Witter, Kathleen W. Wyrwich

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

269 Scopus citations
Original languageEnglish (US)
Pages (from-to)208-215
Number of pages8
JournalPain
Volume125
Issue number3
DOIs
StatePublished - Dec 5 2006

Funding

The authors thank Bryce Reeve for his careful reading, suggestions regarding limitations of IRT, and useful comments on an early draft of this manuscript, and to Paul J. Lambiase and Mary Gleichauf for their invaluable assistance in the organization of the IMMPACT meeting. Abbott Laboratories, Allergan, Alpharma, AstraZeneca, Celgene, Eli Lilly and Co., Endo Pharmaceuticals Inc., GlaxoSmithKline, Johnson and Johnson, Merck and Co., NeurogesX, Novartis Pharmaceuticals, Pfizer, and Schwarz Biosciences provided unrestricted grants to the University of Rochester Office of Professional Education to support the consensus meeting.

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this